MacroGenics Inc (MGNX) Quote

Under the October 2022 collaboration, Gilead holds the exclusive option to license MGD024, exercisable at predefined decision points during the Phase 1 dose escalation study.
While study completion is expected in 2026–2027, these future license points allow for earlier decisions, typically based on meeting safety, tolerability, or early efficacy milestones.
It’s reasonable to expect Gilead could make a license decision before study end, contingent on achieving key Phase 1 data thresholds.

On May 15, 2025, the FDA approved Zynyz for anal canal squamous cell carcinoma (in combination with chemotherapy and as monotherapy) .
This approval likely triggered a regulatory milestone, resulting in a $15?million payment to MacroGenics (confirmed via Incyte's prior disclosures).

Came on, pump it!

MC 130 m
Cash 200 m

royalties capped
cash runway now until first half of 2027.

Powerful short squeeze forming, IMO!
Buy/Sell Ratio
Buy: 1,880,472Neutral: 1,916,649Sell: 1,846,247

MacroGenics Inc. Enters Partnership with Sagard Healthcare Partners for ZYNYZ® Royalty Agreement
70 milions cash

MGNX.......................................................................................p/m

With the FDA approval of Zynyz for the treatment of Merkel cell carcinoma in March 2023, MacroGenics received a $15 million milestone payment. Subsequently, in July 2024, MacroGenics received an additional $100 million upon reaching development-related milestones for the drug. In total, MacroGenics has collected $215 million in milestone payments and remains eligible to receive up to $210 million in additional development and regulatory milestones, as well as $330 million in commercial milestones. Royalties on global sales of Zynyz range from 15% to 24%.

cash at $154.1 million as of March 31, 2025
Mar. 31 2025 -0.78 -0.65 Beat

Dec. 31 2024 -0.44 -0.25 Beat

Cash $ 202 M 31/12
https://ir.macrogenics.com/static-files/13a81fc5-05bf-457d-81b6-e5f7fe3ac290

MGNX 10 Q due MONDAY 3/3

MGNX, 10Q due Monday 2/24

Attention Macrogenics, Inc. (MGNX) Shareholders: Grabar Law Office Investigates Potential Claims on Your Behalf
MGNX | 3 days ago
Philadelphia, Pennsylvania--(Newsfile Corp. - November 7, 2024) - Grabar Law Office is actively investigating claims on behalf of MacroGenics, Inc. (NASDAQ: MGNX) shareholders. If you have continuously held MacroGenics stock since before March 7, 2024, you may be entitled to seek corporate reforms, the return of funds to the company, and potentially receive a court-approved incentive award-all at no cost to you. Visit https://grabarlaw.com/the-latest/macrogenics-shareholder-investigation/ or email jgrabar@grabarlaw.com.

MGNX new 52 week low

MGNX new 52 week low

Lucy runs

Blessings sir!

Well, I never got in. Thought it might of seen upper twos today. Watched it go up 30% though. Got in AMC for some reason. Glad someone made some money here.

I thought I was going to take a loss on my bottom feeding expedition, but instead I am thankful that He blesses me!

Bingo

Finally sold some greened up.
I wait until the issues aren’t deaths

$2.50 Monday ?

These guys are getting hammered! 75%

Down 75% this should be wild today!

Took a starter, gotta gave a bounce here.

Interesting drop today.
Hunting

I’m with ya on entry..planning on a $3ish handle which equals cash on balance sheet( ~ $185mm ish)…. Will do starter in low $4’s(minor $$, then DCA if $3’s ( much more $) …back up truck if deaths not related to clinical’s after internal investigation)

Well, 5 fatalities ready didn't help...geez...Looking for entry

MGNX new 52 week high

MGNX new 52 week high

MGNX new 52 week high
K

MGNX new 52 week high

MGNX

MGNX new 52 week high

MGNX new 52 week high

Lets do this . Can it keep going

MGNX $10.71 +1.48 (+16.03%)
Nice steady climb, as shorts writhe and wail

MGNX I'm going with this
$10.50 +1.27 (+13.76%)
It's a bit of a bail, as I have other work to catch up on
Squeeze of 13% short, on a Citi upgrade to $13

Could turn into a several days hold, for incremental gains. Maybe 5% more today??

https://stockcharts.com/h-sc/ui?s=MGNX

Citigroup Upgrades Macrogenics to Buy, Raises Price Target to $13
BENZINGA 4:20 AM ET Dec-20-2023

Citigroup analyst Yigal Nochomovitz upgrades Macrogenics (MGNX.NaE) from Neutral to Buy and raises the price target from $7 to $13.


Company Profile
SectorHealth CareOpens in a new window
IndustryBiotechnologyOpens in a new window
Company LocationRockville, MD
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 x CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, i

👀

Shes ready to pop above $10

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch


Settlement Date/Short Interest/Percent Change/
Average Daily Share Volume/Days to Cover

01/13/2023 4,373,837 5.28 507,089 8.63
12/30/2022 4,154,346 7.91 575,736 7.22
12/15/2022 3,849,672 (5.66) 633,050 6.08
11/30/2022 4,080,607 (4.36) 1,384,683 2.95
11/15/2022 4,266,434 (15.78) 1,093,099 3.90
10/31/2022 5,065,570 2.50 1,487,531 3.41
10/14/2022 4,942,015 (0.29) 379,450 13.02
09/30/2022 4,956,490 1.85 563,681 8.79
09/15/2022 4,866,500 (0.81) 635,807 7.65
08/31/2022 4,905,995 (13.08) 631,036 7.77
08/15/2022 5,644,366 (0.09) 971,172 5.81
07/29/2022 5,649,639 (17.42) 1,065,799 5.30
07/15/2022 6,841,233 (10.73) 1,407,012 4.86
06/30/2022 7,663,135 (0.99) 2,692,200 2.85
06/15/2022 7,739,527 27.13 1,239,553 6.24
05/31/2022 6,088,004 8.28 827,523 7.36
05/13/2022 5,622,390 10.78 1,337,461 4.20
04/29/2022 5,075,315 3.20 453,486 11.19
04/14/2022 4,917,910 (4.48) 509,771 9.65
03/31/2022 5,148,635 3.46 522,723 9.85
03/15/2022 4,976,392 36.20 868,105 5.73
02/28/2022 3,653,830 4.57 898,618 4.07
02/15/2022 3,494,052 19.83 571,075 6.12
01/31/2022 2,915,828 7.17 457,915 6.37

So what exactly did MGNX do to this diabetes drug?


MacroGenics to get $60M milestone from Provention as FDA approves diabetes drug Tzield


More homework:
https://patents.justia.com/assignee/macrogenics-inc

Looking at MGNX because the chart is intriguing..

VBP is consolidating nicely...

Now I need to figure out what DART and TRIDENT are...


Nov 17, 2022
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics. Teplizumab was acquired by Provention Bio, Inc. in May 2018 pursuant to an asset purchase agreement.

“We are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “We applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of type 1 diabetes.”

Under the agreement, Provention is obligated to pay MacroGenics contingent milestone payments totaling $170 million upon the achievement of certain regulatory approval milestones, including $60 million for the approval of a BLA for a first indication in the United States. In addition, Provention is obligated to make contingent milestone payments to MacroGenics totaling $225 million upon the achievement of certain sales milestones as well as a single-digit royalty on net sales of the product.

Based on MacroGenics’ cash, cash equivalents and marketable securities balance as of September 30, 2022, plus projected and anticipated payments from partners, including timely receipt of the milestone payment from Provention, MacroGenics currently anticipates having a cash runway into late 2024.


http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-and-zai-lab-enter-broad-strategic-collaboration

Nov 17, 2022
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics. Teplizumab was acquired by Provention Bio, Inc. in May 2018 pursuant to an asset purchase agreement.

“We are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “We applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of type 1 diabetes.”

Under the agreement, Provention is obligated to pay MacroGenics contingent milestone payments totaling $170 million upon the achievement of certain regulatory approval milestones, including $60 million for the approval of a BLA for a first indication in the United States. In addition, Provention is obligated to make contingent milestone payments to MacroGenics totaling $225 million upon the achievement of certain sales milestones as well as a single-digit royalty on net sales of the product.

Based on MacroGenics’ cash, cash equivalents and marketable securities balance as of September 30, 2022, plus projected and anticipated payments from partners, including timely receipt of the milestone payment from Provention, MacroGenics currently anticipates having a cash runway into late 2024.

https://www.globenewswire.com/news-release/2022/11/17/2558767/0/en/MacroGenics-Earns-60-Million-Milestone-with-U-S-FDA-Approval-of-Teplizumab.html

$MGNX: What did I tell ya........ hit $4.15 !!!!!!!!!


MUAHHHHhhhhhhhhhh ha ha ha ha ha haaaaaaaaaAAAAAAAAAAAAAA



LOVE IT when a plan comes together like that


Looking for more winners............ stand by


GO $MGNX

$MGNX: Perfeccccccttttttttt Cup & Handle here at 3.50


Added 10k shares here


Get to $4 !!!!!!!!


GOO $MGNX

Where do we go from here?

FDA approval: https://www.macrogenics.com/news/macrogenics-announces-fda-approval-of-margenza-for-patients-with-pretreated-metastatic-her2-positive-breast-cancer/